Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 15,589 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Completed Not applicable Interventional Results available

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

NCT02162420
View directory record Official record
Conditions
Dyskeratosis Congenita, Aplastic Anemia
Interventions
Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, Anti-thymocyte globulin
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
0 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 23, 2026, 1:42 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females

NCT00856596
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot, Foot Fungus, Ringworm
Interventions
Sertaconazole nitrate cream 2%
Drug
Lead sponsor
Jamaica Hospital Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Jamaica, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Oct 23, 2026, 1:42 PM EDT
Terminated Phase 1 Interventional

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

NCT03861403
View directory record Official record
Conditions
Solid Tumors, Advanced Triple Negative Breast Cancer, Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer, Advanced Metastatic Castration-Resistant Prostate Cancer, Advanced Platinum-Resistant Ovarian Cancer
Interventions
TRX518, Cyclophosphamide, Avelumab
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Lafayette, Indiana • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

NCT00003027
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, filgrastim, recombinant interferon alfa, cisplatin, dacarbazine, vinblastine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 4 Interventional Results available

Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria

NCT01701583
View directory record Official record
Conditions
Chronic Urticaria
Interventions
Omalizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

NCT00004141
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Cisplatin, dacarbazine, Granulocyte-macrophage colony-stimulating factor
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

NCT04572841
View directory record Official record
Conditions
Sjögren's Syndrome, Sjogren's Syndrome
Interventions
SAR441344, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin

NCT02592954
View directory record Official record
Conditions
Epidermolysis Bullosa Simplex, Pachyonychia Congenita
Interventions
Jojoba oil with broccoli sprout extract, Jojoba oil (placebo)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities

NCT01544374
View directory record Official record
Conditions
Breast Cancer
Interventions
Tracking & Feedback
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
11
States / cities
Newark, New Jersey • Brooklyn, New York • Elmhurst, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional

Opening the Conversation Study

NCT04806724
View directory record Official record
Conditions
Breast Cancer, Gynecologic Cancer
Interventions
Opening the Conversation, Side by Side
Behavioral
Lead sponsor
Oregon State University
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

NCT05852691
View directory record Official record
Conditions
Breast Cancer
Interventions
Tobemstomig, Pembrolizumab, Nab-Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Alamitos, California • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Terminated Phase 1 Interventional

Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

NCT02607813
View directory record Official record
Conditions
NSCLC, Ovarian Cancer, Melanoma, Other Solid Tumors
Interventions
LXH254, PDR001
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 1 Interventional

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

NCT01276496
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 23, 2026, 1:42 PM EDT
Withdrawn Phase 2 Interventional

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

NCT01832896
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Ecallantide subcutaneous dosing
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Mineola, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2023 · Synced Oct 23, 2026, 1:42 PM EDT
Recruiting Not applicable Interventional

Targeted Remotely-delivered Anti-inflammatory Interventions With Exercise for Rheumatoid Arthritis

NCT06841562
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TRAINERa intensive exercise training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Terminated No phase listed Observational Results available

INFINITY™Total Ankle Replacement Follow-up

NCT03277989
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Not listed
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
21 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Rancho Mirage, California • Fort Collins, Colorado • Libertyville, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 23, 2026, 1:42 PM EDT
Recruiting Not applicable Interventional

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

NCT06903468
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Breast Cancer
Interventions
Novel cavity marking technique
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Precise Oncology Interventions in Nutrition and Training (OnPoint)

NCT06534918
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma
Interventions
Fitbit, Nutrition Course: Group Sessions, Physical Activity Program: Group Sessions, Nutrition Course: One on One Sessions with Registered Dietitian, Physical Activity Program: One on One Sessions with an Exercise Physiologist, Nutrition and Physical Activity Prescription
Other · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Recruiting Phase 1 Interventional

Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques

NCT05642182
View directory record Official record
Conditions
Psoriasis
Interventions
SFA002
Drug
Lead sponsor
SFA Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Pompano Beach, Florida • Fargo, North Dakota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis

NCT03397979
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Infrequent versus Frequent Soaking Baths
Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
6 Months to 11 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional

A Yoga and Wellness Program for Breast Cancer Survivors With Persistent Fatigue

NCT00727662
View directory record Official record
Conditions
Breast Cancer, Fatigue
Interventions
Iyengar Yoga, Wellness Seminar Series
Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
40 Years to 65 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Not applicable Interventional Results available

Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy

NCT01149759
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Cyclosporine A
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 23, 2026, 1:42 PM EDT
Completed No phase listed Observational

Evaluation of EnVisio SmartClip for Intraoperative Localization of Breast Masses

NCT04604561
View directory record Official record
Conditions
Breast Cancer
Interventions
EnVisio SmartClip, EnVisio™ Navigation System
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 23, 2026, 1:42 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors

NCT02573259
View directory record Official record
Conditions
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
Interventions
PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
24
States / cities
Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 23, 2026, 1:42 PM EDT